10x Science: The Founders Who Built the Field Are Now Building the Platform
10x Science is launching an AI‑driven platform that automates molecular characterization of biologic drugs, a step traditionally performed manually by PhD scientists using outdated software. The company’s founders—two Stanford‑trained researchers with Nobel‑linked publications and a veteran YC entrepreneur—bring deep scientific credibility and rapid execution. Pharma’s recent disappointment with AI‑focused discovery tools has shifted demand toward solutions that deliver immediate ROI, and 10x’s recurring‑revenue model fits that need. Early demos with major pharma firms have consistently progressed to contract negotiations, signaling strong product‑market fit.
Food, Not Pills, May Solve Obesity and Heart Disease
The next breakthrough in managing obesity, heart disease, or cognitive decline might not come from a pill. It might come from your food. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your...
FDA Clinical Trials Training Modules
The FDA’s Center for Drug Evaluation and Research has released new clinical‑trial training modules that capture the agency’s latest regulatory intelligence, emerging guidance, and real‑world compliance experience. The curriculum serves as a global benchmark, helping organizations demonstrate regulatory excellence and...
Study Finds Rapamycin May Undermine Exercise Gains in Seniors
An international team led by Brad Stanfield reported that a weekly 6 mg dose of rapamycin blunted the functional gains from a 13‑week home exercise program in 40 sedentary adults aged 65‑85. The placebo group outperformed the rapamycin group on chair‑stand,...
Dayspring Pharma’s CG2001 Foam Hits Primary Endpoint in Phase II AGA Trial of 110 Chinese Men
Dayspring Pharma announced that its CG2001 foam achieved the primary efficacy endpoint in a 30‑week Phase II study of 110 Chinese men with androgenetic alopecia. The combination of 5% minoxidil and 0.075% finasteride delivered roughly 50% greater hair‑growth results versus historic...
Cardiologist Makes ‘Magic,’ Performs First Procedure in US with New-Look Ablation Catheter
Stereotaxis' Magic Magnetic Interventional Ablation Catheter received FDA clearance in January 2026 and was used for the first U.S. procedure this month at Oregon Health & Science University. Electrophysiologist Dr. Nathan McConkey employed the robotically navigated, magnet‑guided catheter to treat...
The Immune System Ages Differently in Men and Women
A new Nature Aging study used single‑cell analysis of over 1 million peripheral blood mononuclear cells from 982 donors aged 19 to 97 to map how the immune system ages. The researchers found that women experience more pronounced age‑related changes in...
GLP‑1 Weight‑Loss Drugs Face Safety Scrutiny as Oral Pills Expand in India
Clinicians caution that GLP‑1 injectables such as Ozempic and Wegovy can trigger gastroparesis and nutritional deficits in patients with chronic disorders, even as one in eight Americans now uses them. At the same time, a wave of oral GLP‑1 tablets...
Leronlimab Shows Early Clinical and Biomarker Activity in Metastatic Colorectal Cancer at AACR 2026
CytoDyn presented early Phase 2 results showing that leronlimab combined with TAS‑102 and bevacizumab markedly reduced circulating tumor DNA in metastatic colorectal cancer patients. CCR5 expression was confirmed in all prescreened tumors, and median ctDNA fell about 70% by week two...
Veeva Systems Beats Q4 Forecast, Posts $836M Revenue, Highlights Life‑Science SaaS Momentum
Veeva Systems reported Q4 FY2026 revenue of $836 million, topping guidance and pushing full‑year revenue to $3.195 billion. The results were driven by R&D Cloud adoption and expanding Vault CRM, while the company forecast 13% subscription‑revenue growth for FY2027.
We Need More Radioactive Drugs. Can We Make Them From Nuclear Waste?
A new wave of radiopharmaceutical cancer treatments is driving unprecedented demand for radioisotopes, prompting companies to extract them from legacy nuclear waste. Researchers at the UK National Nuclear Laboratory are refining radioactive lead from stored waste, while firms like Belgium’s...
Kazmira Therapeutics Launches 1Cannabis Platform to Educate on Medical CBD
Kazmira Therapeutics introduced 1Cannabis, an online education platform that offers three tiered programs on medical cannabidiol (CBD). The suite targets both patients and healthcare providers, aiming to close a knowledge gap as demand for cannabinoid therapies rises.
FDA PreCheck Pilot Program Structure
The FDA PreCheck Pilot Program is a two‑phase initiative aimed at speeding the launch of new U.S. pharmaceutical manufacturing sites. Phase 1 delivers early engagement through Pre‑Operational Reviews and the creation of a Type V Drug Master File that documents facility design,...
Nipocalimab Demonstrates Sustained Disease Control Over Two Years in Generalized Myasthenia Gravis
Johnson & Johnson announced that nipocalimab (Imaavy) sustained disease control in generalized myasthenia gravis for over two years, extending efficacy beyond the initial 24‑week trial to 120 weeks. Patients showed mean reductions of 6.47 points on the MG‑ADL and 5.97...
First Non-INSTI, Tenofovir-Free Regimen DOR/ISL Gains FDA Approval for HIV
The FDA has approved Merck’s Idvysno, a once‑daily, single‑tablet combination of doravirine and islatravir, marking the first non‑INSTI, tenofovir‑free two‑drug regimen for adults with virologically suppressed HIV‑1. Phase 3 trials demonstrated non‑inferior viral suppression compared with standard three‑drug regimens, with only...
Moderna, After Losing US Funding, Rebounds to Start mRNA Bird Flu Vaccine Trial
Moderna has launched a Phase 3 trial of its mRNA‑1018 bird‑flu vaccine, enrolling about 4,000 healthy adults in the United States and the United Kingdom. The study follows the loss of a $766 million U.S. government contract, which had funded earlier development...
FDA Expands Teplizumab-Mzwv Approval to Young Children With Stage 2 T1D
The FDA granted supplemental approval for Sanofi’s teplizumab‑mzwv (Tzield) to treat children as young as one year with stage 2 type 1 diabetes, expanding the prior 8‑year‑and‑up indication. The decision follows interim data from the PETITE‑T1D phase 4 trial, where 23 children received...
AI‑Designed Enzymes Accelerate Corporate Partnerships at SynBioBeta
@SynBioBeta isn't just where startups find investors. It's where Fortune 500 companies find their next technology partner. @IFF is one of the world's largest flavor, fragrance, and biosciences companies, with over $11 billion in revenue and a century-long track record of...
Immunotherapy in Locally Advanced HNSCC: Is There Still Room for New Agents?
In June 2025 the FDA approved MSD’s Keytruda (pembrolizumab) for resectable locally advanced head‑and‑neck squamous cell carcinoma (LA HNSCC) with PD‑L1 CPS ≥ 1, based on the KEYNOTE‑689 trial. A separate adjuvant nivolumab study (NIVOPOSTOP) showed promising results, though regulatory filing is...
STAT+: Gene Therapy Trial for Deafness Adds Evidence to Drug’s Efficacy
Researchers have reported that a gene‑therapy injection dramatically improved hearing in a Chinese clinical trial, with 90% of participants noting significant gains. The study, published in Nature, includes both children and adults, such as a 32‑year‑old who regained functional hearing....
Curve Biosciences Announces Key AI and Clinical Advancements of Whole-Body Intelligence for Chronic Diseases
Curve Biosciences announced two major milestones: its genomic AI foundation model will be presented at the International Conference on Learning Representations (ICLR) and its Whole‑Body Blood Test demonstrated strong performance in a real‑world liver cirrhosis monitoring study. The study enrolled...
Synthetic Smart Proteins that Function as Biological Switches
Researchers at Queensland University of Technology have used artificial‑intelligence design to create synthetic proteins that function as programmable biological switches. The engineered proteins combine receptor and reporter domains, enabling them to detect small molecules, peptides or nucleic acids and generate...
The META-AF Trial
Researchers launched the META‑AF trial to evaluate metformin as an adjunct to catheter ablation in atrial fibrillation patients. The study randomizes roughly 500 participants to receive metformin or placebo beginning two weeks before ablation, with follow‑up through 12 months. Primary...
EMP‑01 Shows Strong Patient‑Reported Gains in Social Anxiety
What incredible news to wake up to! Some weeks ago, @ataibeckley reported positive topline results for EMP-01 (oral R-MDMA, a patent-protected version of #MDMA) for Social Anxiety Disorder(SAD). The data reported was the reduction in symptoms as reported by the treating...
PK/PD Crucial for Next-Gen ADC Development
Wonderful tour de force on ADCs by @raffcolo highlighting the importance of PK/PD going forward with new formats https://t.co/nUpBNNoVil
Northwestern Longevity Clinic Launches Gait‑Based ‘Circuit Breaker’ Study to Gauge Biological Age
Northwestern University's Longevity Clinic has begun the ‘Circuit Breaker’ study, employing gait analysis to estimate participants’ biological age. The initiative seeks to compare age metrics across U.S. and Japanese cohorts while focusing on historically underserved groups.
Moderna Launches mRNA Bird Flu Trial After Funding Loss
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial https://t.co/cKyC9jfWAj by Kristin Jensen $MRNA
Cast SDS-PAGE Gels Using Riboflavin, No TEMED
Here is an alternative way to cast SDS-PAGE gels without needing TEMED, using riboflavin, EDTA, and LED lights. Seems very DIY friendly too.
Maze Therapeutics Secures $150 Million in Stock and Pre‑Funded Warrants Offering
Maze Therapeutics announced the pricing of a $150 million underwritten offering of common stock and pre‑funded warrants. The capital will extend the company’s runway to 2029 and fund the development of its lead candidates for APOL1‑mediated kidney disease and phenylketonuria.
Prelude Tx Unveils Early-Stage KAT6A Degrader
Looking through my #aacr26 collection of posters from yesterday. Prelude Tx have a KAT6A degrader (PRT13722) in early development to compete with inhibitors: https://t.co/23zBtCX8Hs
Personalized CRISPR Poised to Become Standard Care
How individualized CRISPR genome editing can go from rare, expensive use to broader accessibility and a standard of care by @UrnovFyodor and Sadik Kassim @Nature https://t.co/ddc5ASPPAK https://t.co/GOFneIyuai
Virus‑Bursting Nanostructured Surfaces Ready After Decade of Research
Scientists have unveiled a virus‑bursting nanomaterial that mimics insect wings, physically rupturing viral particles on contact. The breakthrough, published in Advanced Science after ten years of work, promises an eco‑friendly alternative to chemical disinfectants for healthcare and public‑transport settings.
Sex Chromosomes Drive Cancer, Autoimmunity, and Brain Disease
Our X and Y chromosomes play a bigger part in health than acknowledged, including cancer, autoimmunity, and neurologic conditions. A new @nature feature https://t.co/IjVNbXzBPB
Merck Expands AI Push; Roche Reports MS Drug Data
Merck adds to pharma’s AI push; Roche details MS drug results https://t.co/VmpWyLhP9A $MRK $RHHBY $TGTX $RCUS $GILD #biotech
Kelun-Biotech to Unveil Three Oncology Trial Results at 2026 ASCO Meeting
Sichuan Kelun-Biotech Biopharmaceutical announced that it will present results from three clinical studies—sac‑TMT plus pembrolizumab, the RET inhibitor lunbotinib, and the novel ADC SKB500—at the 2026 American Society of Clinical Oncology meeting in Chicago. The disclosures underscore the company's expanding...
New Receptor Enables Bat Alphacoronavirus Entry Into Humans
Discovery of a new receptor by which alphacoronavirus from bats can get into human cells and the potential for transmission https://t.co/LE5sTVyfkS @Nature https://t.co/aszqnDMQqE @NatureNV https://t.co/ejnvrvr6BO
VR Therapy Shows Promise for IBS Treatment
Most people think of VR as gaming. In clinic, we’re using it to help patients manage IBS—alongside meds and diet. We’re looking forward to presenting results from our first IBS randomized controlled trial at #DDW26 in Chicago Non-drug therapies are having a moment. @DDWMeeting...
AI Is Spitting Out More Potential Drugs than Ever. This Start-Up Wants to Figure Out Which Ones Matter.
10x Science, a biotech AI startup founded by former Stanford researchers, announced a $4.8 million seed round led by Initialized Capital. The company’s platform combines deterministic chemistry algorithms with AI agents to automatically interpret mass‑spectrometry data, turning raw spectra into actionable...
FDA Approval Could Ignite Peptide Boom and Doping Grey Zone
Peptide space is going to blowup if FDA approves it. Interesting grey area for sports doping.
Redefining ‘First‑in‑Class’ Amid Faster Competing Therapies
How do we define “first in class” when there are others further ahead? This example is from Atheron Therapeutics w/ a CCNE1 degrader #aacr26 https://t.co/s22biREUrt
Deerfield Group Launches Prismatiq for Life Sciences
Deerfield Group unveiled Prismatiq, a field‑enablement platform built specifically for life‑science companies. The solution ties together brand strategy, content, data and engagement insights in a single, CRM‑compatible workspace. By tracking every content interaction, Prismatiq gives reps real‑time analytics to personalize,...
CDC Vaccine Efficacy Report on Halved Winter Hospitalizations Shelved
The #CDC report that showed the #Covid vaccine halved the risk of a recipient needing emergency care or hospitalization this winter has been shelved by HHS, @bylenasun reports. https://t.co/tCNx8LSIKn
New Review Casts Doubt On Alzheimers Drugs But Is Controversial
A new Cochrane review of 17 trials involving more than 20,000 Alzheimer’s patients concludes that amyloid‑targeting monoclonal antibodies deliver only trivial cognitive benefits and carry safety risks. The analysis groups together all anti‑amyloid antibodies—including older failures—thereby diluting the modest gains...
Progress Against Pancreatic Cancer, Part One
Revolution Medicines reported that its RAS‑targeting small molecule daraxonrasib more than doubled overall survival for patients with metastatic pancreatic ductal adenocarcinoma, extending median survival to 13.2 months versus 6.7 months on standard chemotherapy. The drug works by stabilizing a novel...
Immunotherapy Drug Helps Bladder Cancer Patients Avoid Major Organ Removal
A phase‑2 trial led by NYU Langone Health found that adding pembrolizumab (Keytruda) to standard chemotherapy, radiation, and surgery allowed 60% of patients with muscle‑invasive bladder cancer to avoid cystectomy for up to two years. The study, the largest of...
Lilly, Novo Dip as Proposed Medicare Coverage for GLP-1 Pilot Thrown Off Balance
The Centers for Medicare & Medicaid Services (CMS) has indefinitely postponed its BALANCE financing model, a pilot intended to expand Medicare coverage for GLP‑1 obesity drugs. The delay triggered a roughly 2% drop in Eli Lilly’s share price and a 4%...
Ask Your Questions for Upcoming Replimune Chairman Interview
Later today, I'm going over to Replimune to speak with their Chairman about all that's happened. Let me know any questions you'd like me to ask. Scheduled to record at noon and it will be up later in the afternoon.
INBRAIN Neuroelectronics Completes Patient Recruitment for First-in-Human Study Evaluating Its Graphene Cortical Interface
INBRAIN Neuroelectronics announced that patient recruitment is complete for its first‑in‑human trial of a graphene‑based cortical interface. Ten patients were enrolled, and eight underwent surgery without any peri‑operative device failures, yielding complete datasets. The study, run with the University of...
MSD-Backed Ray Locks in $125m to Back Eye Drug Pipeline
Ray Therapeutics announced a $125 million Series B round, led by Janus Henderson Investors with participation from Merck’s venture arm, MRL Ventures and Novo Holdings. The capital will fund late‑stage clinical work and commercial preparation for RTX‑015, its lead gene‑therapy candidate for...
Immunotherapy Offers Hope in Avoiding Bladder Removal for Cancer Patients
A new immunotherapy regimen combining checkpoint inhibitor pembrolizumab with standard chemoradiation has demonstrated a high rate of bladder preservation in patients with muscle‑invasive bladder cancer. In a multinational Phase III trial of 560 participants, 68% of patients avoided cystectomy at...